Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

NASDAQ REGN

$380.28 1.04 (0.27)%

High 381.88 Low 375.50 Volume 264,716 Market Cap 40.13B
12/12/17 2:44 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • Dec 11

    Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA® (aflibercept) Injection for Patients with Wet AMD

    Read on
  • Nov 29

    Regeneron and Decibel Therapeutics Announce Strategic Collaboration to Discover and Develop Therapeutics for Hearing Loss and Tinnitus

    Read on

EVENTS

  • ASH 2017 Presentations
    Dec 9, 2017

  • 29th Annual Piper Jaffray Healthcare Conference
    Nov 28, 2017 | 4:00 PM ET

Events & Presentations

NASDAQ REGN

$380.28 1.04 (0.27)%

High 381.88 Low 375.50 Volume 264,716 Market Cap 40.13B
12/12/17 2:44 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information